Nutra Pharma Corp (NPHC) Change in Receivables (2012 - 2026)

Nutra Pharma has disclosed Change in Receivables across 15 years of filings, most recently posting $109.0 for Q2 2026.

• In Q2 2026, Change in Receivables fell 99.05% year-over-year to $109.0; the TTM figure through Jun 2026 stood at -$8770.0 (down 169.43% YoY), while the FY2025 annual figure was $2305.0, up 74.36% from the prior year.
• Change in Receivables came in at $109.0 for Q2 2026 at Nutra Pharma, down from $285.0 in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $11426.0 in Q2 2025 to a low of -$25733.0 in Q3 2022.
• Average Change in Receivables over 5 years is -$1085.8, with a median of $162.0 recorded in 2023.
• The largest YoY upside for Change in Receivables was 2185.2% in 2025 against a maximum downside of 1756.47% in 2025.
• Over 5 years, Change in Receivables stood at $84.0 in 2022, then jumped by 452.38% to $464.0 in 2023, then jumped by 30.6% to $606.0 in 2024, then plunged by 92.41% to $46.0 in 2025, then surged by 136.96% to $109.0 in 2026.
• Per Business Quant data, the three most recent Change in Receivables figures were $109.0 in Q2 2026, $285.0 in Q1 2026, and $46.0 in Q4 2025.